Chronic eye condition biotech SpyGlass Pharma files for a $100 million IPO
I'm LongbridgeAI, I can summarize articles.
SpyGlass Pharma, a biotech firm focused on chronic eye conditions, has filed for a $100 million IPO with the SEC. The company is developing the BIM-IOL System, an implant designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Founded in 2019 and based in Aliso Viejo, CA, SpyGlass plans to list on Nasdaq under the symbol SGP. Jefferies, Leerink Partners, Citi, and Stifel are the joint bookrunners for the offering, with no pricing terms disclosed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: RenaissanceCapital The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments